Inactive Instrument

Otonomy

Equities

OTIC

US68906L1052

Otonomy, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 04, 2021 at 09:19 pm

Otonomy, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 12.131 million compared to USD 11.120 million a year ago. Net loss was USD 12.512 million compared to USD 11.454 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.37 a year ago. For the half year, operating loss was USD 23.974 million compared to USD 22.682 million a year ago. Net loss was USD 24.722 million compared to USD 23.217 million a year ago. Basic loss per share from continuing operations was USD 0.42 compared to USD 0.75 a year ago.

Latest news about Otonomy

Otonomy, Inc. Announces Executive Changes	28/03/23	CI
Otonomy, Inc. Announces Chief Financial Officer Changes	28/03/23	CI
Otonomy, Inc. Announces Executive Changes	16/02/23	CI
Otonomy, Inc.(OTCPK:OTIC) dropped from S&P TMI Index	28/12/22	CI
Otonomy Shares to be Suspended From Nasdaq Trading	22/12/22	MT
Otonomy, Inc.(OTCPK:OTIC) dropped from NASDAQ Composite Index	22/12/22	CI
Otonomy, Inc.(OTCPK:OTIC) dropped from Russell Microcap Growth Index	22/12/22	CI
Otonomy, Inc.(OTCPK:OTIC) dropped from Russell 3000E Growth Index	22/12/22	CI
Otonomy, Inc.(OTCPK:OTIC) dropped from Russell 3000E Index	22/12/22	CI
Otonomy, Inc.(OTCPK:OTIC) dropped from Russell Microcap Index	22/12/22	CI
Otonomy, Inc.(OTCPK:OTIC) dropped from Russell Microcap Value Index	22/12/22	CI
Otonomy, Inc.(OTCPK:OTIC) dropped from Russell 3000E Value Index	22/12/22	CI
Otonomy Plans to File for Liquidation; Lays off All Employees; Shares Fall	20/12/22	MT
Otonomy, Inc. Plans Reduce Its Workforce	19/12/22	CI
Otonomy, Inc. Announces Executive Changes	19/12/22	CI
Otonomy, Inc. Announces Executive Changes	19/12/22	CI
Otonomy, Inc. Announces Termination of David A. Weber as Chief Executive Officer	19/12/22	CI
Otonomy, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
North American Morning Briefing : Midterm Outcome -2-	09/11/22	DJ
North American Morning Briefing : All Eyes on Bank -2-	14/10/22	DJ
Top Midday Decliners	13/10/22	MT
Otonomy Sees No Clinically Meaningful Improvement With Higher Doses of OTO-413 in Patients With Hearing Loss -- Shares Nosedive	13/10/22	MT
Piper Sandler Downgrades Otonomy to Neutral From Overweight, Lowers Price Target to $0.50 From $3	13/10/22	MT
Otonomy Sees No Clinically Meaningful Improvement With Higher Doses of OTO-413 in Patients With Hearing Loss	13/10/22	MT
Otonomy, Inc Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss	13/10/22	CI

Chart Otonomy

Duration

Period

More charts

Company Profile

Otonomy, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics for neurotology. The Company pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.

Sector

More about the company